Werewolf Therapeutics Inc (HOWL)
2.30
-0.04
(-1.71%)
USD |
NASDAQ |
Jun 26, 12:36
Werewolf Therapeutics Enterprise Value: 1.912M for June 25, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 25, 2024 | 1.912M |
| June 24, 2024 | 14.08M |
| June 21, 2024 | 25.38M |
| June 20, 2024 | 17.12M |
| June 18, 2024 | 25.81M |
| June 17, 2024 | 36.24M |
| June 14, 2024 | 31.03M |
| June 13, 2024 | 41.46M |
| June 12, 2024 | 33.63M |
| June 11, 2024 | 39.28M |
| June 10, 2024 | 41.46M |
| June 07, 2024 | 51.89M |
| June 06, 2024 | 52.32M |
| June 05, 2024 | 56.23M |
| June 04, 2024 | 58.40M |
| June 03, 2024 | 73.61M |
| May 31, 2024 | 124.89M |
| May 30, 2024 | 133.15M |
| May 29, 2024 | 121.41M |
| May 28, 2024 | 115.76M |
| May 24, 2024 | 112.29M |
| May 23, 2024 | 124.46M |
| May 22, 2024 | 112.72M |
| May 21, 2024 | 117.50M |
| May 20, 2024 | 107.94M |
| Date | Value |
|---|---|
| May 17, 2024 | 105.34M |
| May 16, 2024 | 112.29M |
| May 15, 2024 | 110.98M |
| May 14, 2024 | 114.46M |
| May 13, 2024 | 94.04M |
| May 10, 2024 | 119.68M |
| May 09, 2024 | 142.27M |
| May 08, 2024 | 138.36M |
| May 07, 2024 | 148.79M |
| May 06, 2024 | 160.09M |
| May 03, 2024 | 164.00M |
| May 02, 2024 | 164.43M |
| May 01, 2024 | 161.83M |
| April 30, 2024 | 171.39M |
| April 29, 2024 | 189.64M |
| April 26, 2024 | 192.82M |
| April 25, 2024 | 169.41M |
| April 24, 2024 | 177.22M |
| April 23, 2024 | 179.38M |
| April 22, 2024 | 164.21M |
| April 19, 2024 | 155.98M |
| April 18, 2024 | 154.68M |
| April 17, 2024 | 153.37M |
| April 16, 2024 | 143.40M |
| April 15, 2024 | 138.20M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-93.41M
Minimum
Dec 07 2022
376.67M
Maximum
Jul 02 2021
72.95M
Average
14.08M
Median
Jun 24 2024
Enterprise Value Benchmarks
| CEL-SCI Corp | 61.31M |
| AIM ImmunoTech Inc | 11.80M |
| IGC Pharma Inc | 31.39M |
| NovaBay Pharmaceuticals Inc | 2.939M |
| Protalix BioTherapeutics Inc | 66.51M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -16.19M |
| Revenue (Quarterly) | 0.742M |
| Total Expenses (Quarterly) | 17.90M |
| EPS Diluted (Quarterly) | -0.39 |
| Profit Margin (Quarterly) | -2.18K% |
| Earnings Yield | -47.39% |
| Normalized Earnings Yield | -47.39 |